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Abstract
 
Targeted disruption of death receptor (DR)6 results in enhanced CD4
 
  
 
T cell expansion and T
helper cell type 2 differentiation after stimulation. Similar to T cells, DR6 is expressed on rest-
ing B cells but is down-regulated upon activation. We examined DR6
 
 
 
/
 
  
 
B cell responses both
in vitro and in vivo
 
. 
 
In vitro, DR6
 
 
 
/
 
  
 
B cells undergo increased proliferation in response to
anti–immunoglobulin M, anti-CD40, and lipopolysaccharide. This hyperproliferative response
was due, at least in part, to both increased cell division and reduced cell apoptosis when com-
pared with wild-type B cells. Consistent with these observations, increased nuclear levels and
activity of nuclear factor 
 
 
 
B transcription factor, c-Rel, and elevated Bcl-x
 
l 
 
expression were
observed in DR6
 
 
 
/
 
  
 
B cells upon stimulation. In addition, DR6
 
 
 
/
 
  
 
B cells exhibited higher
surface levels of CD86 upon activation and were more effective as antigen-presenting cells in
an allogeneic T cell proliferation response. DR6
 
 
 
/
 
  
 
mice exhibited enhanced germinal center
formation and increased titers of immunoglobulins to T-dependent as well as T-independent
type I and II antigens. This is the first demonstration of a regulatory role of DR6 in the activa-
tion and function of B cells.
Key words: hyperproliferation • TNFR superfamily • apoptosis • CD40 • spleen
 
Introduction
 
Members of the TNF/TNFR family play a critical role in
the regulation of inflammation and immune responses
along with lymphoid tissue homeostasis (1, 2). Many
TNF-related ligands and their cognate receptors induce
regulatory signals in primary cells and stimulate diverse
signaling pathways, including the activation of caspases,
 
the translocation of nuclear factor (NF)
 
*
 
-
 
 
 
B, and the acti-
vation of mitogen-activated protein kinases such as c-Jun
amino-terminal kinase or extracellular signal regulatory ki-
nase (1). Consequently, several TNF/TNFR family mem-
bers have been shown to be essential for both the etiology
and progression of adaptive immune responses. Specifi-
cally, those involving interactions between T and B cells,
such as CD40L/CD40, OX40L/OX40, and BlyS/
[TACI/BCMA/BAFF-R], have been shown to contrib-
ute to the generation of an effective immune response (3–
17). These investigations indicate that TNF/TNFR family
member interactions can control several aspects of B cell
biology including development, homeostasis, activation,
and tolerance.
Members of the NF-
 
 
 
B transcription factor family, in-
cluding c-Rel, are regulated by many TNF family mem-
bers and their receptors and are essential for mitogen-
induced proliferation of B cells (18–21). C-Rel–deficient B
cells proliferate poorly and have survival defects after stim-
ulation (21). C-Rel is also required for cell cycle progression
of B cells (22). It has been demonstrated, however, that
transgenic expression of Bcl-x
 
L
 
, a c-Rel gene target, can
rescue c-Rel–deficient B cells from their survival defects
(23). Thus, regulating the transcriptional activity of NF-
 
 
 
B
family members is a vital step in controlling B cell func-
tions, especially during activation.
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Abbreviations used in this paper:
 
 BCR, B cell receptor; CFSE, 5-(and
6)-carboxyfluorescein diacetate, succinimidyl ester; DR, death receptor;
GMSA, gel mobility shift assay; NF, nuclear factor; NP, 4-hydroxy-3-
nitrophenylacetyl; PEC, peritoneal exudate cell; PNA, peanut agglutinin;
rt, room temperature; TBS, Tris-buffered saline.T
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Role of Death Receptor 6 in B Cell Immune Responses
 
Death receptor (DR)6 is a death domain–containing re-
ceptor within the TNFR superfamily and its expression is
observed in a number of tissues, including lymphoid tissues
(24–26). However, the complete physiological functions of
DR6 remain unknown. Recent studies of DR6-deficient
(DR6
 
 
 
/
 
 
 
) mice have demonstrated that DR6 serves as an
important regulator for CD4
 
  
 
T cell proliferation and Th
differentiation (25, 26). However, because T and B cell in-
teractions provide mutually beneficial signals that are con-
ducive to a protective immune response, targeted disrup-
tion of DR6 may also have intrinsic effects on B cells and
humoral immune responses.
In this study, DR6 was shown to be expressed on naive
B cells from WT mice and rapidly down-regulated upon
activation. The proliferation and cell division of DR6
 
 
 
/
 
 
 
B cells in response to stimulation in vitro was enhanced
compared with WT B cells
 
.
 
 The absence of DR6 aug-
mented B cell functions in vivo as evidenced by increased
production of Ig isotypes in response to both T cell–
dependent and T cell–independent antigens. Histological
analysis revealed enhanced splenic germinal center forma-
tion in DR6
 
 
 
/
 
  
 
mice after in vivo antigen challenge. In
addition, DR6
 
 
 
/
 
  
 
B cells exhibited higher nuclear levels
of c-Rel, increased expression of Bcl-x
 
L
 
, and decreased
cell apoptosis upon activation compared with WT B cells.
Together, these findings offer evidence that DR6 provides
a regulatory mechanism for B cell activation and humoral
immune responses.
 
Materials and Methods
 
Mice.
 
The generation and maintenance of DR6
 
 
 
/
 
  
 
mice
along with WT littermates have been previously described (25).
BALB/c mice (H-2
 
d
 
) were purchased from Harlan. All animals
were kept in American Association for Accreditation of Labora-
tory Animal Care–accredited pathogen-free facilities and pro-
vided standard laboratory diet and water ad libitum.
 
B Cell Culture and Proliferation Assay.
 
Splenic cell suspen-
sions were isolated from 8–10-wk-old WT and DR6
 
 
 
/
 
  
 
mice
by homogenizing spleens between frosted glass slides (Fisher
Scientific) and removing RBCs with ACK lysing buffer (Bio-
Whittaker). B cells were enriched by positive selection using
magnetic anti-B220 microbeads and autoMACS
 
® 
 
magnetic
cell sorter (Miltenyi Biotec). The purity of isolated B cells was
subsequently analyzed by flow cytometry and found to be 93–
97% B220
 
 
 
. Purified B cells were cultured in triplicate wells
(5 
 
  
 
10
 
5 
 
cells/well) of a Costar
 
® 
 
96-well tissue culture plate
(Corning, Inc.) in RPMI 1640 medium (Invitrogen) supple-
mented with 2 mM 
 
l
 
-glutamine, 25 mM Hepes, 100 U/ml
penicillin, 100 
 
 
 
g/ml streptomycin, 5.5 
 
  
 
10
 
 
 
5 
 
M 2-ME, and
10% FCS (all supplements are from Invitrogen) at 37
 
 
 
C, 5%
CO
 
2 
 
with or without different stimulators for 72 h. Stimula-
tors included 5 
 
 
 
g/ml LPS (
 
Escherichia coli
 
 055:B5; Difco), 10
 
 
 
g/ml anti-CD40 (HM40-3; BD Biosciences), and 20 
 
 
 
g/ml
whole rabbit anti–mouse IgM (Zymed Laboratories). Prolifer-
ation was measured by incorporation of 1 
 
 
 
Ci/well [
 
3
 
H]thy-
midine (ICN Biomedicals) during the last 12 h of culture us-
ing a filtermate harvester (Packard Instrument Co.) and a
1450 microbeta liquid scintillation counter (Amersham Bio-
sciences).
 
Flow Cytometry.
 
Cell subset analysis was performed by pre-
paring cell suspensions from RBC-lysed spleen, bone marrow
(one femur), PBL, and peritoneal exudate cell (PEC). Cells
were suspended (1–2 
 
  
 
10
 
6 
 
cells/sample) in PBS plus 0.1%
BSA (Fraction V; Invitrogen) and initially blocked with Fc
Block™ (BD Biosciences) at 4
 
 
 
C for 30 min. For analysis of B
cell purity after positive magnetic sorting, cell suspensions were
stained with CD45R/B220-FITC or CD4-FITC (both from
BD Biosciences). For analysis of mature, immature, and mar-
ginal zone B cell populations in the spleen and bone marrow,
cell suspensions were first stained with CD45R/B220-Cy-
Chrome™ (BD Biosciences). Mature and immature B cells
were identified using anti–mouse IgM-FITC (BD Biosciences)
and anti–mouse IgD-PE (Southern Biotechnology Associates,
Inc.), whereas marginal zone B cells were identified using
CD21/35 (CR2/CR1)-FITC and CD23-PE (both from BD
Biosciences). Cell suspensions from the spleen, PBL, and PEC
were analyzed for B1 B cells using CD45R/B220-FITC and
CD5-PE (both from BD Biosciences). Isotype control Abs in-
cluded FITC-, PE-, and CyChrome™-conjugated rat IgG
 
2a
 
 
 
and rat IgG
 
2b
 
  
 
(both from BD Biosciences). 4 
 
  
 
10
 
4 
 
lympho-
cyte-gated events were collected and the percentage for each
gated cell population was multiplied by the total number of live
cells (determined by trypan-blue exclusion) recovered from
each site to provide absolute numbers.
Phenotypes of WT and DR6
 
 
 
/
 
  
 
B220
 
  
 
cells in cultures gener-
ated as described above were determined at specific time points
by staining with anti-CD80 (B7.1)-PE, CD86 (B7.2)-PE, or
MHC class II I-A
 
b
 
, CD54 (ICAM-1), CD69 (Very Early Activa-
tion Antigen), and CD95 (Fas) along with hamster IgG
 
 
 
 and 
 
 
 
,
rat IgG
 
2a
 
 
 
, and mouse IgG
 
2a
 
  
 
isotype controls (all from BD Bio-
sciences). Surface expression of DR6 was determined by staining
with either biotinylated goat anti–human DR6 antibody or con-
trol biotinylated normal goat IgG (R&D Systems) and specific Ab
binding was detected with streptavidin-PE (BD Biosciences).
Cross-reactivity of the anti–human DR6 antibody with murine
DR6 was confirmed by flow cytometric and Western immuno-
blot analysis (unpublished data). 10,000 lymphocyte-gated events
were collected and determined to be live cells via duplicate sam-
ples stained with propidium iodide (Molecular Probes). The
binding of annexin V to cell surface phosphatidylserine was as-
sayed on anti-IgM, anti-CD40, and LPS-activated B cells from
WT and DR6
 
 
 
/
 
  
 
mice using the Annexin V-FITC apoptosis de-
tection kit (BD Biosciences). All flow cytometric data were col-
lected with a FACSort™ (Becton Dickinson) using CellQuest™
software (Becton Dickinson).
 
Cell Division Analysis.
 
Splenic B cells from naive mice were
labeled with 5-(and 6)-carboxyfluorescein diacetate, succinimidyl
ester (CFSE; Molecular Probes) according to established proto-
cols (27). In brief, suspensions at 10
 
7 
 
cells/ml in HBSS were pre-
warmed to 37
 
 
 
C. CFSE was then added to a final concentration
of 1 
 
 
 
M and the cells were incubated for 10 min at 37
 
 
 
C with
occasional mixing, followed by the addition of 10
 
  
 
volume of
ice-cold RPMI medium containing 10% FCS. After washing
twice with RPMI medium, CFSE-labeled cells were cultured as
described above with or without either 5 
 
 
 
g/ml LPS, 10 
 
 
 
g/ml
anti-CD40, or 20 
 
 
 
g/ml anti-IgM for 24, 48, and 72 h before
flow cytometric analysis. Lymphocyte-gated populations were
determined to be live cells via duplicate samples stained with pro-
pidium iodide (Molecular Probes). Histogram peaks denoting
specific daughter cell generations were determined by initially an-
alyzing the CFSE mean fluorescence intensity of cells left in me-
dia alone, and then identifying peaks that corresponded to one-T
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half of this mean fluorescence intensity (cell division one) and of
subsequent generations.
 
Western Blot and Gel Mobility Shift Assay (GMSA).
 
1.2 
 
  
 
10
 
7
 
WT and DR6
 
 
 
/
 
  
 
splenic B cells were stimulated with 10 
 
 
 
g/ml
anti-IgM or 1 
 
 
 
g/ml anti-CD40, collected, and washed with
PBS. Cytoplasmic and nuclear protein extracts were isolated at
time points of 0, 30 min, and 4 h using NE-PER™ Nuclear and
Cytoplasmic Extraction Reagents (Pierce Chemical Co.) and
quantified for total protein content by BCA assay (Pierce Chemi-
cal Co.). Equivalent amounts of protein were separated using
SDS-PAGE, transferred to nitrocellulose membranes, and blots
were probed with antibodies specific to c-Rel (C; Santa Cruz
Biotechnology, Inc.).
For Bcl-x
 
L 
 
Western blots, whole cell lysates from B cell cul-
tures were stimulated with anti-IgM or anti-CD40 for 0 and 4 h
and prepared in 1
 
  
 
RIPA buffer (150 mM NaCl, 1% NP-40, 50
mM Tris, pH 8.0, 0.5% sodium deoxycholate, and 0.1% SDS).
Cell lysates were quantified for total protein content by BCA as-
say (Pierce Chemical Co.) and equivalent amounts were loaded
for SDS-PAGE followed by transfer to nitrocellulose membranes.
Bcl-x
 
L 
 
in anti-CD40–stimulated samples was detected with rabbit
polyclonal anti–Bcl-x
 
L 
 
(Cell Signaling Technology, Inc.), whereas
mouse monoclonal anti–Bcl-x
 
L 
 
(H-5; Santa Cruz Biotechnology,
Inc.) was used to detect the protein in anti-IgM–treated samples
as the stimulus was a rabbit anti–mouse IgM (
 
  
 
chain–specific)
antibody that was detected by the original secondary antibody
(horseradish peroxidase anti–rabbit). All blots were probed with
mouse anti–
 
  
 
actin (Sigma-Aldrich) as a loading control. C-Rel,
Bcl-x
 
L
 
, and 
 
  
 
actin proteins were detected with horseradish per-
oxidase–conjugated anti–rabbit or anti–mouse secondary anti-
bodies (Jackson ImmunoResearch Laboratories) and developed
by SuperSignal
 
® 
 
West Pico Chemiluminescent Substrate kit
(Pierce Chemical Co.).
GMSAs were performed as previously described (28) using 2
 
 
 
g nuclear proteins and 0.5 
 
 
 
g poly [d (I-C)]. The following oli-
gonucleotides (Sigma-Aldrich) containing binding sites for c-Rel
were used as probe: first strand: 5
 
 
 
-gggAGTTGAGGGGAC-
TTTCCCAGGC-3
 
 
 
; second strand: 5
 
 
 
-GCCTGGGAAAGTC-
CCCTCAACT-3
 
 
 
. Small letters indicate linker nucleotides for
labeling purposes. Cold homogenous oligonucleotide was used
for competition assays to test the specific binding. Anti–c-Rel (C;
Santa Cruz Biotechnology, Inc.) was added after the nuclear pro-
teins were incubated with the probe and used for supershift as-
says.
 
MLR.
 
Splenic B cell cultures from DR6
 
 
 
/
 
  
 
mice and WT
littermates (H-2K
 
b
 
) were stimulated with 10 
 
 
 
g/ml anti-CD40
for 24 h. Anti-CD40–treated B cells were then washed and irra-
diated with 3,000 rads from a 
 
137
 
Cs source at 250 rads/min and
used as allogeneic stimulator cells (29). Responder splenic CD3
 
 
 
T cells from BALB/c mice (H-2K
 
d
 
), isolated by positive mag-
netic cell sorting (Miltenyi Biotec), were mixed with the stimu-
lator cells. Both cell populations were seeded at 4 
 
  
 
10
 
5 
 
cells/
well in a 96-well plate in 0.2 ml of Iscove’s modified Dulbecco’s
medium supplemented with 10% FCS, 2 mM glutamine, 100
U/ml penicillin, and 100 
 
 
 
g/ml streptomycin. After 72 h of
stimulation, wells were pulsed with 1 
 
 
 
Ci of [
 
3
 
H]thymidine and
incubated an additional 6 h before harvesting and counting as de-
scribed above.
 
Serum Immunoglobulin Analysis.
 
8–10-wk-old DR6
 
 
 
/
 
  
 
mice
and WT littermates were challenged intraperitoneally with 100
 
 
 
l PBS (CaCl2- and MgCl2-free; Invitrogen) solution containing
either 10  g 4-hydroxy-3-nitrophenylacetyl (NP)-conjugated fi-
coll (NP24-AECM-Ficoll; Biosearch Technologies), 20  g NP-
LPS (Biosearch Technologies), or 50  g NP-conjugated KLH
(NP36-KLH; Biosearch Technologies) in 100  l solution of CFA
(Difco) on day 0. Serum was collected before (preimmune) and
on days 4, 7, and 14 after challenge. NP-specific Ig isotypes from
each group were quantified by coating ELISA plates (Costar®)
overnight at 4 C with 10  g/ml NP25-BSA (Biosearch Technol-
ogies) in 50 mM carbonate/bicarbonate buffer (pH 9.6; Sigma-
Aldrich). Plates were blocked for 1 h at room temperature (rt)
with 1% gelatin in Tris-buffered saline (TBS; Sigma-Aldrich) and
washed three times with TBS plus 0.05% Tween-20 (TBS-T;
Sigma-Aldrich). Serum samples serially diluted in 0.1% gelatin/
TBS were added and incubated at rt for 1 h. After three washes
with TBS-T, plates were incubated for 30 min at rt with alkaline
phosphatase–conjugated goat anti–mouse IgM and IgG isotypes
(SBA Clonotyping™ System/AP; Southern Biotechnology Asso-
ciates, Inc.). Plates were washed five times with TBS-T, followed
by the addition of p-nitrophenyl phosphate substrate solution and
read after 25 min at 405 nm on a  max kinetic microplate reader
(Molecular Devices). All data were quantified against the purified
mouse isotype standards (Mouse Immunoglobulin Standard
Panel; Southern Biotechnology Associates, Inc.). BSA-coated
plates gave no detectable binding of serum isotypes.
Immunohistochemistry. 8–10-wk-old DR6 /  mice and WT
littermates were challenged intraperitoneally with 50  g NP-
KLH in CFA as described above. Tissues were fixed overnight in
zinc-buffered formalin (Fisher Scientific) and then transferred to
70% ethanol before processing through paraffin. Five micron sec-
tions were generated by microtome and sections were placed on
positive-charged slides. Slides were baked overnight at 60 C, de-
paraffinized in xylene, and rehydrated through graded alcohols to
water (30). Antigen retrieval was performed by immersing the
slides in Target Retrieval Solution (DakoCytomation) for 20 min
at 90 C in a water bath, cooling at rt for 10 min, washing in wa-
ter, and then proceeding with immunostaining. All subsequent
staining steps were performed on the Dako Autoimmunostainer.
Incubations were performed at rt and TBS plus 0.05% Tween 20,
pH 7.4 (DakoCytomation), was used for all washes and diluents.
Slides were blocked with protein blocking solution (DakoCyto-
mation) for 25 min. After washing, 10  g/ml of either biotin-
ylated anti–mouse CD45R/B220 (BD Biosciences) or biotin-
ylated peanut agglutinin (PNA; Vector Laboratories) was added
to the slides and incubated for 60 min. Streptavidin–horseradish
peroxidase kit (LSAB2; DakoCytomation) was then used along
with a 3,3 -diaminobenzidine chromagen. Slides were removed
from the autostainer and counter-stained with hematoxylin for 30
s followed by permanent mounting and light microscopy analysis.
Statistical Analysis. The statistical significance of data pre-
sented in Figs. 1 D, 3, A–C, and 5 D was determined by two-
sampled Student’s t test as noted.
For in vitro annexin V binding data (see Fig. 3, G–I) and in
vivo immunoglobulin data (see Fig. 6), a mixed effects model was
fit using the compound symmetry covariance structure. The
terms used in this model were “Treatment” (WT vs. DR6 / ),
“Day” (4, 7, and 14 for Fig. 6 and 24, 48, and 72 h for Fig. 3, G–I),
and “Treatment*Day” interaction as fixed effects and “Ani-
mals nested within Treatment” as the random effect. Baseline
protein expression levels were included as covariates in the model
whenever appropriate. Because the distribution of the protein ex-
pression levels was not symmetric, Box-Cox transformation
method (31) was used to transform the data to ensure symmetry
and homogenous variance. The mixed effect model was fit for
this transformed data using the JMP software, version 4.0.2.
Within the framework of this mixed effects model comparisonsT
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between DR6 /  and WT treatments were made for days 4, 7,
and 14 (see Fig. 6), and 24, 48, and 72 h (Fig. 3, G–I). Statistical
significance was claimed when the two-tailed P values were
 0.05.
Results
B Cell Development and Populations in DR6 /   Mice.
Although the two previous reports on DR6 /  mice indi-
cated no gross histological defects nor differences in
B220  cell populations (25, 26), we evaluated whether the
absence of DR6 affected B cell development and/or pop-
ulations of conventional B2, B1, and marginal zone B
cells. Cell preparations from the spleen and bone marrow
of naive DR6 /  or WT mice were analyzed for mature
and immature B cell populations by staining for surface
levels of IgM and IgD (Fig. 1). The absence of DR6 did
not significantly affect the mature (IgMdull and IgDhigh) or
immature (IgMhigh and IgDdull) compartment in the spleen
or bone marrow with respect to either percentage or abso-
lute numbers (Fig. 1, A and D; P   0.09 for all compared
populations). Additional analysis of the spleen for marginal
zone B cells (B220 , CR1/CR2 , and CD23low) also re-
vealed no significant (P   0.9) differences in percentages
or absolute numbers when compared with WT littermates
(Fig. 1, B and D). To determine if B1 cell populations
were present in DR6 /  mice, primary cells from the
spleen, PBL, and PEC were analyzed for CD5   and
B220  populations. DR6 /  mice exhibited similar per-
centages of B1 cells in all three sites (Fig. 1 C) and abso-
lute numbers of these cells were not significantly different
(Fig. 1 D; P   0.09 for all three sites). In addition, no sig-
nificant differences in B cell turnover in naive DR6 / 
and WT mice were observed as measured by bromode-
oxyuridine incorporation (unpublished data). Together,
these data suggest that targeted disruption of DR6 causes
no gross defects in B cell lineage development or periph-
eral populations.
B Cell Surface Expression of DR6. Previously, it was
shown that DR6 transcripts were expressed in adult lym-
phoid tissue such as spleen and lymph node (25, 26). To
examine if surface levels of DR6 are expressed and regu-
lated on B cells, B220  cells from the spleens of naive
DR6 /  and WT mice were stained for surface DR6 be-
fore and after stimulation with either anti-IgM, anti-CD40,
or LPS and subsequently analyzed by flow cytometry. Sur-
face DR6 was detected on naive WT B cells before stimu-
lation (Fig. 2 A, 0 h), however, this expression was down-
regulated after treatment with either anti-IgM, anti-CD40,
or LPS (Fig. 2 B). Gradual loss of surface DR6 appeared to
occur during the initial 12–24 h of culture and was unde-
tectable above the goat Ig control by 24 h after stimulation
(Fig. 2 B). In contrast, DR6 expression was still detected
on WT B cells after 24 h in media alone, indicating that
loss of DR6 surface expression was activation dependent.
B220  cells from DR6 /  mice exhibited no positive stain-
ing above the goat Ig control (Fig. 2 C). These data suggest
that DR6 surface expression is lost upon stimulation and
may play a role in activation.
Enhanced B Cell Proliferation in the Absence of DR6. The
differential expression of DR6 between resting and acti-
vated B cells implies that DR6 might play a regulatory
role in B cell responses. To address this, B cell prolifera-
tion in response to different stimulators was examined in
vitro. Purified B cells (93–97% B220 ) were activated
with either anti-IgM, anti-CD40, or LPS for 72 h and
Figure 1. Mature, immature, marginal zone,
and B1 B cell populations in DR6 /  mice. Sin-
gle cell suspensions of spleen, bone marrow (1 fe-
mur), PBL, and PEC from groups (n   5) of na-
ive DR6 /   ( / ) and WT (wt) littermates
mice were isolated and analyzed by flow cytome-
try. (A) Splenocytes and B220 -gated bone
marrow cells were analyzed for proportions of
mature (M, IgMdull and IgDhigh) and immature
(I, IgMhigh and IgDdull) B cell populations as de-
noted by gates. (B) Analysis of marginal zone B
cells (CR1/CR2high and CD23low) from B220 -
gated splenocytes of DR6 /  and WT mice as in-
dicated by the gate. (C) Percentages of B1 B cells
(B220  and CD5 ) from spleen, PBL, and PEC
of naive DR6 /  mice and WT littermates. (D)
Absolute numbers of mature, immature, B1, and
marginal zone B cells (MZB) are represented and were determined by multiplying the total tissue live
cell count by the percentages described above from DR6 /  and WT mice. Tissues include spleen
(SPL), bone marrow (BM), PBL, and PEC. Results shown are representative of two independent ex-
periments. Values shown represent the mean and error bars represent the SD. *, P   0.01.T
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proliferation was measured. Levels of [3H]thymidine in-
corporation in DR6 /  B cells using all three stimuli were
significantly higher than that of B cells from WT mice
(Fig. 3, A–C). These 72-h cultures were essentially free of
contaminating CD4  T cells ( 0.9%; unpublished data)
and little to no [3H]thymidine incorporation was observed
in the absence of stimulation (Fig. 3, A–C). These results
suggest that DR6 affects B cell proliferation induced by a
variety of stimuli.
Absence of DR6 Promotes Cell Division Progression and Sur-
vival of Mitogen-stimulated B Cells. Although DR6 /   B
cells show increased [3H]thymidine incorporation after mi-
togen stimulation compared with WT B cells, it is unclear
whether this is a consequence of increased cell division, de-
creased apoptosis, or possibly a combination of both. To
address these issues, we performed cell division and cell
death analysis on mitogen-activated splenic B cells from
WT and DR6 /  mice. Before culture with either anti-
IgM, anti-CD40, or LPS, B cells from naive mice were la-
beled with CSFE and CFSE fluorescence was monitored
after 24, 48, and 72 h of stimulation (27). Relative to B
cells from WT mice, an increased number of cell division
cycles was clearly demonstrated in DR6 /  B cells at all
time points and with all three stimuli (Fig. 3, D–F). These
data indicate that DR6 influences B cell proliferation by
regulation of cell division.
To examine whether there was a direct effect of DR6 on
B cell apoptosis, annexin V binding was analyzed 24, 48,
and 72 h after the treatment of WT and DR6 /  B cells
with either anti-IgM, anti-CD40, or LPS (Fig. 3, G–I).
Fig. 3, G–I, shows that the percentage of annexin V  pro-
pidium iodide  DR6 /  B cells was significantly lower
compared with that of WT B cells with all three stimuli
with the exception of LPS stimulation at 24 h. Together,
these results indicate that enhanced cell division progres-
sion and decreased apoptosis contribute to the increased
proliferative response of DR6 /  B cells as measured by
[3H]thymidine incorporation.
Increased Levels and Activity of Nuclear C-Rel and Elevated
Bcl-xL Expression upon Activation of DR6 /  B Cells. C-Rel
is one of the critical transcription factors controlling B cell
proliferation and survival especially after activation by B
cell receptor (BCR) or CD40 cross-linking (21, 22, 32).
Cultured B cells from WT and DR6 /  mice were stimu-
lated with anti-IgM or anti-CD40, and at different time
points nuclear and cytoplasm extracts were prepared and
used for Western blot analysis. As shown in Fig. 4 A, in-
creased nuclear levels of c-Rel were observed in DR6 /  B
cells upon stimulation with anti-CD40 and anti–IgM.
DR6 /  B cells exhibited marked increases of nuclear
c-Rel compared with WT B cells after 30 min stimulation
with either anti-CD40 or anti–IgM (Fig. 4 A, top). DR6 / 
B cells still displayed a higher abundance of c-Rel in the
nucleus than WT B cells after 4 h of anti-IgM stimulation
(Fig. 4 A, bottom), whereas anti-CD40–treated B cells
showed no difference.
Consistent with the Western blot data described above,
increased nuclear c-Rel–DNA complexes were observed
using nuclear fractions of activated DR6 /  B cells as vi-
sualized by GMSA analysis (Fig. 4 B, top). In addition, the
c-Rel–DNA complex was supershifted by the addition of
anti–c-Rel Ab (Fig. 4 B, bottom), indicating that the in-
crease of nuclear c-Rel from activated DR6 /  B cells
correlates with increased protein–DNA complexes. These
Figure 2. Down-regulated DR6 sur-
face expression on activated WT B cells.
B cells were purified from spleen using
positive selection as described in Materi-
als and Methods. B220  cells were acti-
vated with 20  g/ml anti-IgM, 10  g/
ml anti-CD40, or 5  g/ml LPS and
then analyzed for DR6 expression by
flow cytometry. Surface expression of
DR6 was measured before (A) and 12
and 24 h after plating (B). Solid line his-
tograms represent anti-DR6 staining
and dashed line histograms represent
biotinylated goat Ig control. (C) DR6-
deficient (DR6 / ) B cells were used
for confirming Ab specific staining. Loss
of DR6 surface expression on WT cells
between 12 and 24 h was dependent on
stimulation, as cultures left in media
alone (no stimulus) for 24 h had no sig-
nificant loss of DR6 surface expression.
Y axis represents relative cell number
and x axis represents log10 fluorescence
intensity. Data shown are representative
of three independent experiments.T
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data suggest that DR6 may function in part by regulating
signaling pathways that result in increasing nuclear levels
of c-Rel.
To test whether increased nuclear levels of c-Rel im-
pacted specific gene expression, we investigated the expres-
sion Bcl-xL, which is transcriptionally controlled by c-Rel
Figure 3. Effect of DR6 deficiency on B cell proliferation, cell division, and survival. B
cells isolated from spleens of 8–10-wk-old DR6-deficient (DR6 / ) and WT littermate
control mice were stimulated with 20  g/ml anti-IgM (A), 10  g/ml anti-CD40 (B), or 5
 g/ml LPS (C) as described in Materials and Methods. Cells were cultured in triplicates in
96-well plates for 72 h and B cell proliferation was measured by [3H]thymidine incorpora-
tion during the final 12 h of culture. Values shown represent the mean and error bars repre-
sent the SD. *, P   0.01. (D–F) For B cell division measurement, purified B cells were la-
beled with fluorescence dye CFSE as described in Materials and Methods. Cells were then
incubated for 24, 48, and 72 h with either 20  g/ml anti-IgM (D), 10  g/ml anti-CD40
(E), or 5  g/ml LPS (F) as indicated. Loss of CFSE fluorescence, indicating cell division
progression, was measured by flow cytometry. Lymphocyte-gated populations were deter-
mined to be live cells via duplicate samples stained with propidium iodide. Solid filled histo-
grams indicate activated cells and unfilled histograms represent cultures at t   0. Histogram
markers indicate the percentage of cells that underwent at least three rounds of division. (G–I)
Splenic B220  cells of DR6-deficient (DR6 / ) and WT control mice were stimulated
with either 20  g/ml anti-IgM (G), 10  g/ml anti-CD40 (H), or 5  g/ml LPS (I). At 24,
48, and 72 h of culture, annexin V binding activity of cells was analyzed by flow cytometry
as described in Materials and Methods. Values shown represent the mean percentage of an-
nexin V /propidium iodide  cells in duplicate cultures and error bars represent the standard
deviation. *, P   0.05; **, P   0.01.T
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and is important for cell survival (33). WT and DR6 /  B
cells were treated for 4 h with anti-IgM or anti-CD40 and
total cell lysates were probed for Bcl-xL by Western blot.
Elevated Bcl-xL protein was observed in activated DR6 / 
B cells compared with WT B cells at 4 h for both stimuli
(Fig. 4 C). These data suggest that decreased apoptosis ob-
served in DR6 /  B cells might be due in part to increased
Bcl-xL expression early after activation.
Up-regulation of CD86 Expression and Enhanced APC
Function in DR6 /  B Cells. B cell activation leads to the
up-regulation of a number of cell surface molecules that
are important for T–B cell collaboration (34, 35). Interac-
tions between CD40 and CD40L can lead to the up-regu-
lation of a number of B cell surface costimulatory mole-
cules including those of the B7 family (35). We compared
up-regulation of several of these molecules on B cells from
WT and DR6 /  mice after activation. Stimulation with
either anti-IgM, anti-CD40, or LPS resulted in an in-
creased number of cells with high CD86 surface expres-
sion in DR6 /  B cell cultures compared with WT at 24 h
(Fig. 5 A). In contrast, surface levels of CD80, CD54,
CD69, CD95, and MHC class II I-Ab were expressed at
similar levels on DR6 /  and WT B cells (Fig. 5 B and
unpublished data). CD86 surface expression was also mon-
itored at 0, 12, 24, and 36 h with either anti-IgM, anti-
CD40, or LPS stimulation. Peak CD86 expression for
both DR6 /  and WT B cells occurred from 12–24 h,
however, DR6 /  cultures consistently had 15–28% more
cells with high CD86 expression compared with WT cul-
tures. By 36 h, anti-IgM–treated DR6 /  and WT cul-
tures had CD86 levels that returned to basal levels,
whereas DR6 /  cultures with anti-CD40 or LPS stimula-
tion still exhibited 15–19% more CD86high-expressing cells
compared with WT cultures (unpublished data). These
data suggested that DR6 might be involved in regulating
B cell CD86 expression, which is necessary for T cell pro-
liferation in response to antigen presentation on B cells
(36, 37).
To address whether DR6 affects their physiological
function as APC, B cells of DR6 /  mice and WT litter-
mates were stimulated with anti-CD40 for 24 h. Activated
B cells were then washed, irradiated, and used in mixed
lymphocyte stimulation assays with allogeneic T cells as re-
sponding cells. Fig. 5 C illustrates that an augmented T cell
proliferative response was observed when activated
DR6 /  B cells were used as stimulator cells. These results
suggest that DR6 might be involved in B cell APC func-
tion, which in turn could affect the outcome of B and
CD4  T cell interactions that occur during adaptive im-
mune responses in vivo.
Increased T-dependent and T-independent Humoral Responses
in DR6 /  Mice. The effects of DR6 deficiency in hu-
moral responses to T-dependent antigen were compared by
challenging DR6 /  and WT mice with NP-conjugated
KLH (NP-KLH) in CFA. In agreement with an earlier
study (26), we detected modest increases in NP-specific
IgM but a large increase in IgG1 at day 7 in DR6 /  mice
compared with WT (Fig. 6, top). Although IgG2a was not
significantly different between DR6 /  and WT mice, the
absence of DR6 greatly increased serum levels of NP-spe-
cific IgG2b and IgG3 (Fig. 6, top).
Data presented so far would indicate an intrinsic role for
DR6 in B cell activation. To investigate this further, WT
and DR6 /  mice were immunized with either a T-inde-
Figure 4. Increased nuclear levels and activ-
ity of c-Rel and elevated Bcl-xL expression in
activated DR6 /  B cells. (A) Western blot
analysis of c-Rel in cytoplasmic and nuclear ex-
tracts from DR6-deficient ( / ) and WT (wt)
B cell cultures. Purified splenic B cells were
stimulated with or without 10  g/ml anti-IgM
or 1  g/ml anti-CD40 for 30 min or 4 h as in-
dicated. Cytoplasmic (C) and nuclear (N) ex-
tracts were prepared as described in Materials
and Methods. C-Rel was detected with specific
anti–c-Rel Ab after SDS-PAGE. Equal
amounts of either cytoplasmic or nuclear pro-
tein extracts were loaded into wells and data
shown are representative of two independent
experiments. (B) GMSA with nuclear fractions
of DR6 /  and WT B cells activated with anti-
IgM or anti-CD40 for 0.5 or 4 h as described in
Materials and Methods. Nuclear c-Rel from ac-
tivated DR6 /  B cells bound to its specific
DNA probe (top) and supershifted with the
addition of anti–c-Rel antibody (bottom).
Middle bands were nonspecific binding, as they
were not competed by cold homologous oligo-
nucleotide. (C) B cells from DR6-deficient
( / ) or WT (wt) were either untreated or treated with anti-IgM or anti-CD40 for 4 h and total cell lysates were prepared in 1  RIPA buffer as de-
scribed in Materials and Methods. After SDS-PAGE and Western transfer, Bcl-xL in anti-CD40–stimulated samples was detected with rabbit polyclonal
anti–Bcl-xL, whereas mouse monoclonal anti–Bcl-xL was used to detect the protein in anti-IgM–treated samples as the stimulus was a rabbit anti–mouse
IgM antibody that was detected by the original secondary, anti–rabbit antibody. All blots were probed with mouse anti–  actin as a loading control. Data
shown are representative of two independent experiments.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
58 Role of Death Receptor 6 in B Cell Immune Responses
pendent type I (NP-LPS) or type II (NP-Ficoll) antigen.
Immunization with NP-LPS induced higher average NP-
specific titers of all isotypes in DR6 /  mice compared
with WT littermates, although overall levels of IgG1, IgG2a,
and IgG2b were lower than for NP-KLH immunization
(Fig. 6, middle). Immunization with NP-Ficoll resulted in
significantly (P   0.01) higher titers of NP-specific IgM
and IgG1 in DR6 /  mice compared with WT mice,
whereas IgG2b was higher at days 4–7 and IgG3 was higher
at day 4 in DR6 /  mice (Fig.6, bottom). There was no
significant difference of IgG3 between WT and DR6 / 
mice at days 7 and 14. These results indicate that targeted
disruption of DR6 not only affects in vivo T-dependent
humoral responses, but also has effects on T-independent
type I and II humoral responses.
Germinal Center Formation Is Augmented in the Absence of
DR6. During T-dependent B cell responses, germinal
centers are the anatomical site of T–B cell interactions and
represent a physiological hallmark of Th activity. To deter-
mine if DR6 deficiency affects germinal center formation,
spleens of WT and DR6 /  mice immunized with NP-
KLH were removed at day 14 and analyzed by immuno-
histochemistry. Although spleen sections from naive WT
and DR6 /  mice displayed no gross anatomical differ-
ences (25 and unpublished data), spleen sections from im-
munized DR6 /  mice stained for B220 exhibited in-
Figure 5. Enhanced expression of CD86 and APC function by activated DR6 /  B cells. (A)
B220  cells from DR6 /  or WT mice were stimulated with 20  g/ml anti-IgM, 10  g/ml anti-
CD40, or 5  g/ml LPS for 24 h and analyzed by flow cytometry for CD86 surface expression. Solid
line histograms represent CD86 staining of activated cells and dashed line histograms represent un-
stimulated levels. (B) As in A but LPS-stimulated B cell cultures were analyzed for surface expression
of MHC class II I-Ab (top) and CD80 (bottom). Y axis represents relative cell number and x axis rep-
resents log10 fluorescence intensity. (C) For allogeneic T cell proliferation assay, responding T cells (H-2d) were purified from BALB/c mice and cultured
in the presence or absence of irradiated WT or DR6-deficient ( / ) B cells that were previously stimulated with 10  g/ml anti-CD40 for 24 h and
then irradiated. After 5 d of incubation, the proliferation of allogeneic T cells was measured by [3H]thymidine incorporation in the last 6 h of pulse. Val-
ues shown represent the mean and error bars represent the SD. *, P   0.01. Data shown are representative of three independent experiments.
Figure 6. Enhanced T-dependent and
T-independent type I and II responses in
DR6 /  mice. Cohorts (n   5) of DR6-
deficient (DR6 / ) and WT mice were im-
munized with either 50  g NP-KLH
(T-dependent), 20  g NP-LPS (T-inde-
pendent type I), or 10  g NP-Ficoll
(T-independent type II) on day 0. Serum
NP-specific IgM and different IgG isotypes
levels were measured from preimmune
mice (pre) and at days 4, 7, and 14 after
challenge by ELISA as described in Materi-
als and Methods. Values shown represent
mean values of five mice from each geno-
type group and error bars represent the
SEM. *, P   0.05; **, P   0.01.T
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creased cellularity and size of the B cell area of white pulp
compared with WT spleens (Fig. 7, top). Staining with
PNA revealed an enhanced size of germinal centers in
DR6 /  mice compared with WT controls (Fig. 7, bot-
tom), indicating that the absence of DR6 also enhances the
development of anatomical locations of B cell proliferation
after antigen challenge.
Discussion
Intracellular signals generated by interactions between a
number of TNF/TNFR family members have been shown
to be critical for the function of B lymphocytes at multiple
steps of humoral immune responses (1, 3–17, 35). Stimula-
tion of CD40 on B cells is essential for Ig isotype class
switching of T-dependent antibody responses and germinal
center formation (38, 39). Interactions between B lympho-
cyte stimulator (BLyS) and its receptors have been shown
to influence multiple aspects of B cell biology, including
development, proliferation, homeostasis, and humoral re-
sponses, especially to T-independent type II antigens (5–
13, 15–17). Absence of DR6 was previously shown to
enhance CD4  T cell proliferation along with Th2 differ-
entiation and cytokine production (25, 26). In the course of
in vivo responses, however, CD4  T cells undergo multiple
interactions with other cell types to establish protective
immunity. During T cell–dependent B cell responses, in-
teractions between antigen–BCR, MHC class II–peptide-
TCR, CD28–CD86, and CD40–CD40L generate intra-
cellular signals in both T and B cells that are necessary for
the progression of a humoral response (40, 41). Surface ex-
pression of DR6 was detected on resting B220  cells and
like CD4  T cells (25), this expression was down-regulated
after stimulation (Fig. 2). These data suggested that DR6
may also have functions intrinsic to B cells that occur early
in responses.
We investigated the impact of DR6 deficiency on mod-
ulating B cell responses both in vitro and in vivo. DR6 / 
mice exhibited no gross defects in B cell development or in
peripheral populations of conventional B2, B1, or marginal
zone B cells (Fig. 1). The in vitro proliferation of DR6 / 
B cells was markedly increased after stimulation with either
anti-IgM, anti-CD40, or LPS (Fig. 3, A–C). These re-
sponses were due, at least in part, to increased cell mitosis
(Fig. 3, D–F) and reduced apoptosis (Fig. 3, G–I) after acti-
vation. Together, these in vitro results indicate that lack of
DR6 in B cells can influence their activation, proliferation,
and survival.
Figure 7. Expanded B cell areas and enhanced germinal center formation in DR6 /  mice. For immunohistological analysis, spleens from cohorts (n  
3) of DR6-deficient (DR6 / ) or WT mice were removed at 14 d after NP-KLH challenge and sections were prepared as described in Materials and
Methods. B220  areas of the splenic white pulp are shown in brown at 10  (top). Germinal centers were visualized by PNA  staining of successive
spleen sections described above. PNA  areas (in brown) within the B cell follicles indicate germinal centers (bottom, 40 ). B220 and PNA staining was
visualized with 3,3 -diaminobenzidine chromagen and sections were counterstained with hematoxylin.T
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NF- B/Rel family members are among the many tran-
scription factors implicated in controlling gene expression
in B lymphocytes and also can serve to protect cells from
apoptotic signals (22, 32, 33). C-Rel is expressed at high
levels in lymphoid cells (19). C-Rel–deficient B lympho-
cytes have impaired proliferative responses to anti-IgM,
anti-CD40, or LPS and exhibit defects in their ability to
receive survival signals through anti-IgM or LPS stimula-
tion (21, 23). In our study, increased nuclear levels of
c-Rel capable of forming c-Rel–DNA complexes were
observed in activated DR6 /  B cells, suggesting that DR6
may regulate B cell proliferative responses, at least in part,
through a c-Rel–mediated pathway. Our data is consistent
with previous studies (21, 22) indicating that c-Rel is a
critical transcription factor for both cell division and apop-
tosis, and DR6 appears to be involved in regulating nu-
clear c-Rel activity. The increase of nuclear c-Rel in
DR6 /  B cells could be caused by accelerating the nu-
clear translocation by increased NF- B pathway activation.
However, we did not observe any differences in NF- B ac-
tivation between WT and DR6 /  B cells after stimulation
(unpublished data), suggesting the increase of nuclear c-Rel
is not due to increased NF- B activation and accelerated
c-Rel nuclear translocation.
Bcl-2 family proteins have been shown to play an im-
portant role for the survival of various stages of B lympho-
cytes and Bcl-xL is crucial for the survival and maturation of
germinal center B cells (42). The expression of apoptosis
inhibitor Bcl-xL is known to be transcriptionally regulated
by c-Rel (33). Enhanced expression of Bcl-xL was observed
in activated DR6 /  B cells (Fig. 4 B), suggesting that in-
creased nuclear c-Rel levels and Bcl-xL expression may
contribute to both increased proliferation and decreased
apoptosis of activated DR6 /  B cells.
The CD28–CD86 interaction has been demonstrated to
be important for T cell activation (43). Increased expres-
sion of CD86 upon stimulation of B cells through BCR or
CD40 was found to contribute to enhanced production of
IgG1 and IgE (44). Additionally, it was recently reported
that signals induced by cross-linking of CD86, but not
CD80, on activated B cells enhanced proliferation and pro-
duction of IgG1 along with augmenting levels of Bcl-xL
(45). Upon activation, a greater percentage of cultured
DR6 /  B cells exhibited high CD86 surface expression
compared with WT B cells (Fig. 5 A). In addition, our data
demonstrated increased allogeneic T cell proliferation in
response to previously activated DR6 /  B cells as APC
(Fig. 5 C). The increased CD86 expression of DR6 /  B
cell populations may contribute, via costimulatory signals,
to increased T cell responses and/or may also provide sig-
nals directly to the B cell itself.
CD4  T cells can influence antibody isotype secretion to
T-dependent antigens. Th2 cells contribute to IgG1 and
IgE isotype generation whereas Th1 cells influence IgG2a
and IgG3 isotypes (46, 47). Previous studies showed that
upon KLH challenge, production of Th2 cytokines was
markedly higher in the activated DR6 /  T cells (25, 26).
Consistent with these previous studies, DR6 /  mice im-
munized with NP-KLH exhibited increased IgM and IgG1
isotypes at day 7, however, no significant difference was
observed in IgG2a levels compared with WT controls.
In addition, we observed an increase in the size of ger-
minal centers in DR6 /  spleens after T-dependent antigen
challenge (Fig. 7). Previous studies have shown that CD28
is a crucial factor for germinal center formation (48) and
CD28 expression is up-regulated in DR6 /  T cells com-
pared with WT mice (25). This, along with higher B cell
CD86 expression, suggests that DR6 /  B cells received
stronger stimulating signals in the T cell–rich regions of the
white pulp to promote the formation of germinal centers.
Although the absence of DR6 affects T-dependent hu-
moral responses, it is unclear whether this is mediated
through intrinsic effects on B cells, the preferential Th2 dif-
ferentiation of CD4  T cells, or a combination of both.
T-independent antigens are also critical for host defense
and involve the stimulation of B cells by antigen-present-
ing dendritic cells without the initial involvement of
CD4  T cells (49). In addition to T-dependent humoral
responses, DR6 /  mice also displayed increased Ig levels
in response to T-independent type I (NP-LPS) and type II
(NP-Ficoll) antigens. These data further indicate that
DR6 serves a regulatory role that is intrinsic to B cells, al-
though it does not exclude the possibility that DR6 influ-
ences cellular responses in both the innate and adaptive
arms of host defense.
Our current studies provide evidence that DR6 has a
fundamental role in activation-induced B cell expansion,
survival, and humoral responses. Therefore, modulation of
the DR6 signaling pathway might be able to control the
extent of B cell responses in addition to CD4  T cell re-
sponses and potentially provide therapeutic benefits to treat
certain immune system disorders, such as asthma, allergy,
and various autoimmune diseases.
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